Kite Pharma (KITE): Reiterate Buy Ahead of ZUMA-1 Results - Mizuho

August 9, 2016 8:56 AM EDT
Get Alerts KITE Hot Sheet
Price: $47.01 +3.73%

Rating Summary:
    14 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade KITE Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Mizuho Securities analyst, Eric Criscuolo, reiterated his Outperform rating on shares of Kite Pharma (NASDAQ: KITE) and expects the Phase II ZUMA-1 trial to meet its ORR endpoint, with the results now expected by the end of 3Q. Full data is expected at ASH, and a FDA filing remains on track for year-end. The analyst thinks KITE could have the NHL market to itself for a year or more. The filing on 3 month data still raises concerns, but he remains confident. An Investor Day October 18 could provide significant clarity on commercialization and long-term strategy.

The investor day on October 18th, should provide additional details on launch preparations, including logistics, initial targeting, and pricing/ reimbursement, which remains a key piece of the puzzle. Pricing in the $300,000 range is a distinct possibility however the analyst is modeling $200,000. He is also looking forward to updates on the AMGN collaboration (relatively quiet since the original announcement in early 2015), as well as updated timelines for current and future ZUMA trials (including earlier-stage DLBCL) and the progress in solid tumors.

No change to the price target of $80.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $58.25 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment